Abstract

According to the World Health Organization (WHO), high risk for developing diabetes relates to two distinct states, impaired fasting glucose (IFG) defined as fasting plasma glucose (FPG) from 100-125mg/dl and impaired glucose tolerance (IGT) defined as post-glucose plasma level from 140- 199mg/dl based on 2-hours oral glucose tolerance test (OGTT). Metformin has pleiotropic effects leading to improved lipid and cholesterol metabolism, reduced inflammation and inhibition of cell growth. Pioglitazone is dependent on the presence of insulin to exert its advantageous effects and preserve β-cells of the islets of Langerhans, but does not act same as an insulin secretagogue. Improved glycaemic control results in lowering of circulating HbA1C and insulin levels in type 2 DM patients. Material and Methods: Present study is Comparative, Prospective, randomized, Open-label, Single Center, Parallel group study conducted at Index Medical college. Study was conducted in prediabetes patients for assessment of effects of Metformin and Pioglitazone. All patients were evaluated at baseline, 3 months for clinical and physical examination and laboratory investigation. Present Study was conducted in prediabetes Patients for assessment of effect of Metformin and Pioglitazone on lipid levels attending the outpatient department of Medicine in Index Hospitals and College. Results: In the lipid profile, both groups showed a decrease at three months in serum total cholesterol (30 mg/dl decrease from baseline to 3 months in the PGZ group versus 20 mg/dl decrease from baseline to 3 months in the MF group). The PGZ group achieved a significant decrease in serum triglyceride levels 45 mg/dl from baseline to 3 months and 11 mg/dL from baseline to 3 months in the MF group. Moreover, HDL showed an Increase at three months (5 mg/dl from baseline in the PGZ group versus 4 mg/dl from baseline in the MF group and low-density lipoprotein (LDL) cholesterol levels (30 mg/dl from baseline to 3 months in the PGZ group versus 30 mg/dl from the baseline to 3 months in the MF group). Conclusion: After 3 months’ treatment with Metformin and Pioglitazone, showed statically significant reduction in Lipid Profile values. Whereas, after 3 months of treatment with Metformin and Pioglitazone caused reduction in Lipid Profile values statistically significant decreased compare with Metformin and Pioglitazone. On the hand, Metformin reduced PPBG level, statistically highly significant compared with Pioglitazone group.

Description